Medicare GLP-1 Bridge Program: 5 Things to Know Before July 2026
The $50/month Medicare GLP-1 Bridge launches July 1, 2026. Here are 5 things Part D enrollees must prepare now to lock in Wegovy, Zepbound, or Foundayo.
The Medicare GLP-1 Bridge Program goes into effect July 2026, providing temporary coverage for beneficiaries who lost employer-plan GLP-1 access at the start of the year. There are five things every Medicare-eligible patient should know.
Key takeaways
- Bridge coverage runs through December 2026 with possible extension
- Patients must demonstrate prior continuous GLP-1 use for at least 6 months
- Coverage applies to brand-name semaglutide, tirzepatide, and Foundayo only
- Compounded medications are not eligible for Bridge reimbursement
- Enrollment is through your existing Medicare plan, not a separate sign-up
Who qualifies
Medicare beneficiaries who were on a GLP-1 medication continuously for at least 6 months and lost coverage between January and June 2026. You'll need pharmacy fill records to demonstrate continuity.
Patients new to GLP-1 therapy in 2026 are not currently eligible for Bridge coverage.
How to enroll
Most Medicare Advantage plans are handling Bridge enrollment automatically based on pharmacy claims. If you don't see Bridge coverage reflected in your plan portal by mid-July, contact your plan directly with prior fill records.
Original Medicare patients should consult their Part D plan documentation for plan-specific instructions.